A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

The errant growth of this protein is responsible for triggering an increase in tangled threads of another protein called tau and the development of Alzheimer’s disease — at least according to the ...

Over the past few years, data and drugs associated with the amyloid hypothesis have been mired in various controversies relating to data integrity, regulatory approval, and drug safety.

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...

Yet despite decades of research, no treatment has been created that arrests Alzheimer’s cognitive deterioration, let alone reverses it. That dismal lack of progress is partly because of the infinite ...

Alzheimer's disease is likely caused by stalled protein processing in the brain, according to a new study.

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy ...

Merck was among a clutch of companies that tried to bring a now-defunct category amyloid-targeting therapies for Alzheimer's – the BACE inhibitors – through clinical development.